Letermovir vs Valganciclovir for Cytomegalovirus Prophylaxis After Kidney Transplant-Reply

JAMA. 2023 Nov 14;330(18):1803-1804. doi: 10.1001/jama.2023.18025.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Acetates / therapeutic use
  • Antiviral Agents* / administration & dosage
  • Antiviral Agents* / therapeutic use
  • Chemoprevention / methods
  • Cytomegalovirus Infections* / etiology
  • Cytomegalovirus Infections* / prevention & control
  • Cytomegalovirus*
  • Kidney Transplantation* / adverse effects
  • Quinazolines / therapeutic use
  • Valganciclovir* / therapeutic use

Substances

  • Acetates
  • Antiviral Agents
  • letermovir
  • Quinazolines
  • Valganciclovir